Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00387426 · OUTCOME

Number of Participants With Objective Clinical Response to Sunitinib Therapy

Sunitinib in Treating Patients With Idiopathic Myelofibrosis · Source last updated 2014-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
After two 6-week treatment courses (12 weeks)

What was measured

Participant response assessed after two cycles of therapy according to categories: 1) complete response, 2) partial response, 3) clinical improvement, 4) stable disease 5) progressive disease, 6) early death from malignant disease, 7) early death from toxicity, 8) early death because of other cause, or 9) unknown (not assessable, insufficient data).

Analysis population: All participants assessed for response.

Groups in this outcome

Sunitinib

37.5 mg orally daily for 6-week cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Sunitinib14

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Sunitinib1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Participant response assessed after two cycles of therapy according to categories: 1) complete response, 2) partial response, 3) clinical improvement, 4) stable disease 5) progressive disease, 6) early death from malignant disease, 7) early death from toxicity, 8) early death because of other cause, or 9) unknown (not assessable, insufficient data).
groups
  1. description
    37.5 mg orally daily for 6-week cycle
    id
    OG000
    title
    Sunitinib
param Type
NUMBER
population Description
All participants assessed for response.
reporting Status
POSTED
time Frame
After two 6-week treatment courses (12 weeks)
title
Number of Participants With Objective Clinical Response to Sunitinib Therapy
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice